BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

TransMolecular, Inc. 

Corporate Office
840 Memorial Drive, Second Floor
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-995-3050 Fax: 617-995-3049


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
Morphotek Inc. Announces Acquisition of Tumor Targeting Assets From TransMolecular, Inc. 4/5/2011 8:45:00 AM
TransMolecular, Inc.'s 131I-TM601 Shown to Improve Survival in Recurrent Malignant Glioma 10/23/2009 8:31:02 AM
TransMolecular, Inc.'s 131I-TM601 Successfully Localizes to Multiple Tumor Types without Targeting Healthy Tissue 6/17/2009 9:25:10 AM
TransMolecular, Inc. Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at American Society of Clinical Oncology Annual Meeting 6/1/2009 9:16:41 AM
TransMolecular, Inc. Announces Presentation of Data Highlighting Anti-angiogenic and Tumor-targeting Properties of TM601 at American Society of Clinical Oncology Annual Meeting 5/21/2009 9:25:54 AM
TransMolecular, Inc. Presents New Information on Distinct Anti-Angiogenic Mechanism-of-Action of TM601 5/4/2009 11:00:26 AM
TransMolecular, Inc. Announces Presentation of Data Confirming Anti-angiogenic Method-of-Action of TM601 at ARVO Annual Meeting 4/30/2009 11:32:03 AM
TransMolecular, Inc. Appoints Robert Radie President and Chief Executive Officer 4/7/2009 7:22:23 AM
TransMolecular, Inc. Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma 12/22/2008 9:32:24 AM
TransMolecular, Inc. Reaches Special Protocol Agreement with FDA for an 131I-TM601 Phase 3 Trial in Newly Diagnosed Glioblastoma Multiforme Patients 12/2/2008 6:25:23 AM
1234